Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1076039.RAbauot1X9SscpC9Sv8rDnS4g4B2lkC5Bqx-Yex6E1rAA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1076039.RAbauot1X9SscpC9Sv8rDnS4g4B2lkC5Bqx-Yex6E1rAA130_assertion type Assertion NP1076039.RAbauot1X9SscpC9Sv8rDnS4g4B2lkC5Bqx-Yex6E1rAA130_head.
- NP1076039.RAbauot1X9SscpC9Sv8rDnS4g4B2lkC5Bqx-Yex6E1rAA130_assertion description "[These include v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations for the selection of patients with advanced colorectal cancer who are unlikely to benefit from anti-epidermal growth factor receptor antibodies (cetuximab or panitumumab), epidermal growth factor receptor (EGFR) mutations for selecting patients with advanced non-small cell lung cancer (NSCLC) for treatment with tyrosine kinase inhibitors (gefitinib or erlotinib), v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations for selecting patients with advanced melanoma for treatment with anti-BRAF agents (vemurafenib and dabrafenib), and anaplastic lymphoma receptor tyrosine kinase (ALK) translocations for identifying patients with NSCLC likely to benefit from crizotinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1076039.RAbauot1X9SscpC9Sv8rDnS4g4B2lkC5Bqx-Yex6E1rAA130_provenance.
- NP1076039.RAbauot1X9SscpC9Sv8rDnS4g4B2lkC5Bqx-Yex6E1rAA130_assertion evidence source_evidence_literature NP1076039.RAbauot1X9SscpC9Sv8rDnS4g4B2lkC5Bqx-Yex6E1rAA130_provenance.
- NP1076039.RAbauot1X9SscpC9Sv8rDnS4g4B2lkC5Bqx-Yex6E1rAA130_assertion SIO_000772 23656699 NP1076039.RAbauot1X9SscpC9Sv8rDnS4g4B2lkC5Bqx-Yex6E1rAA130_provenance.
- NP1076039.RAbauot1X9SscpC9Sv8rDnS4g4B2lkC5Bqx-Yex6E1rAA130_assertion wasDerivedFrom befree-2016 NP1076039.RAbauot1X9SscpC9Sv8rDnS4g4B2lkC5Bqx-Yex6E1rAA130_provenance.
- NP1076039.RAbauot1X9SscpC9Sv8rDnS4g4B2lkC5Bqx-Yex6E1rAA130_assertion wasGeneratedBy ECO_0000203 NP1076039.RAbauot1X9SscpC9Sv8rDnS4g4B2lkC5Bqx-Yex6E1rAA130_provenance.